ClinicalTrials.Veeva

Find clinical trials for Multiple Sclerosis (MS) in Indianapolis, IN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Sclerosis
Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Chronic Progressive Multiple Sclerosis
Amyotrophic Lateral Sclerosis
Motor Neuron Disease
Muscle Spasticity

Multiple Sclerosis (MS) trials near Indianapolis, IN, USA:

Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis (VISTA)

This is a randomized, double-blind study of PIPE-307 or placebo in subjects with relapsing-remitting multiple sclerosis. Subjects w...

Enrolling
Relapsing Remitting Multiple Sclerosis
Drug: Placebo
Drug: PIPE-307 Dose B

Phase 2

Contineum Therapeutics

Indianapolis, Indiana, United States and 15 other locations

American (AA) and Hispanic/Latino (HA) patients with relapsing multiple sclerosis (RMS) receiving treatment with Ocrelizumab. The s...

Active, not recruiting
Multiple Sclerosis, Relapsing
Drug: Ocrelizumab

Phase 4

Genentech
Genentech

Indianapolis, Indiana, United States and 30 other locations

administered orally once daily in participants with Relapsing Multiple Sclerosis (RMS). Participants who complete the double-blind ...

Active, not recruiting
Relapsing Multiple Sclerosis
Drug: Evobrutinib
Drug: Placebo (match to Teriflunomide)

Phase 3

Merck KGaA (EMD Serono)
Merck KGaA (EMD Serono)

Indianapolis, Indiana, United States and 278 other locations

This is a randomized, double blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and pharmacokinetics of a higher dose...

Active, not recruiting
Multiple Sclerosis
Drug: Ocrelizumab
Drug: Antihistamine

Phase 3

Roche
Roche

Avon, Indiana, United States and 125 other locations

The primary purpose of this phase 3b study is to assess efficacy after transition from a current DMT to ublituximab, as measured by T1 Gadolinium (Gd...

Enrolling
Relapsing Multiple Sclerosis
Biological: Ublituximab

Phase 3

TG Therapeutics
TG Therapeutics

Indianapolis, Indiana, United States and 19 other locations

A study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple...

Active, not recruiting
Multiple Sclerosis, Primary Progressive
Drug: Placebo matched to ocrelizumab
Drug: Fenebrutinib

Phase 3

Roche
Roche

Indianapolis, Indiana, United States and 192 other locations

A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible parti...

Active, not recruiting
Relapsing Multiple Sclerosis
Drug: Teriflunomide
Drug: Fenebrutinib

Phase 3

Roche
Roche

Avon, Indiana, United States and 117 other locations

) neo-antigen in subjects with relapsing multiple sclerosis (RMS)....

Enrolling
Relapsing Multiple Sclerosis
Biological: 13-valent pneumococcal conjugate vaccine (13-PCV)
Biological: Tetanus toxoid (TT) containing vaccine (Td, Tdap)

Phase 3

Novartis
Novartis

Indianapolis, Indiana, United States and 298 other locations

This is a Phase IIIb, single-arm, multicenter, OLE study. Participants receiving ocrelizumab as an investigational medicinal product (IMP) in a Roche...

Active, not recruiting
Multiple Sclerosis
Drug: Ocrelizumab

Phase 3

Roche
Roche

Indianapolis, Indiana, United States and 242 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems